TACE并射频容性加热治疗原发性肝癌临床疗效评估

Clinical Efficacy Evaluation of Transcatheter Arterial Chemoembolization Combined with Radiofrequency Capacitive Treatment for Primary Hepatic Carcinoma

[目的]评价TACE合并射频容性加热对原发性肝癌的疗效和毒副反应。[方法]原发性肝癌患者55例,分为TACE合并射频容性加热组(治疗组,25例)和常规灌注化疗栓塞(TACE)组(对照组,30例)。[结果]治疗后肿瘤生长率治疗组为-0.41±0.25,对照组为-0.18±0.28;AFP下降治疗组为15例(88.0%),对照组为11例(55.0%),两组比较差异均有显著性(P<0.05)。近期有效率治疗组为68.0%;对照组为53.3%。治疗组中热疗3例局部出现皮下脂肪结节,1例出现约0.5cm大小的水泡。毒副反应两组比较差异无显著性(P>0.05)。[结论]TACE合并射频容性加热治疗原发性肝癌能提高临床疗效,不增加毒副反应。

[Purpose] To evaluate clinical efficacy and toxicity of transcatheter arterial chemoembolization（TACE） combined with radiofrequency capacitive heating（RCH） treatment for primary hepatic carcinoma（PHL）. [Methods] Fifty-five cases with PHC were enrolled in this study. The patients were divided into two groups： study group（TACE＋RCH） 25 cases and control group（TACE alone） 30 cases. [Resuits] The carcinoma growth rates in study group and in control group were -0.41±0.25 and -0.18±0.28 respectively, with significant difference （P〈0.05）. Fifteen cases （88.0%） in study group and 11 cases （55.0%） in control group showed AFP decrease with significant difference （P〈0.05）. Hyperthermic fat nodus and small burned blister were observed in 3 eases and 1 case in study group respectively. The difference of adverse reaction between the study and control group was not significantly（P〉0.05）. [Conclusion] TACE combined with RCH can improve the clinical efficacy in treatment for PHC without increasing toxicity.